tiprankstipranks
Trending News
More News >
Xvivo Perfusion AB (SE:XVIVO)
:XVIVO
Sweden Market

Xvivo Perfusion AB (XVIVO) Stock Forecast & Price Target

Compare
1 Followers
See the Price Targets and Ratings of:

XVIVO Analyst Ratings

Hold
2Ratings
Hold
1 Buy
0 Hold
1 Sell
Based on 2 analysts giving stock ratings to
Xvivo
Perfusion AB
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

XVIVO Stock 12 Month Forecast

Average Price Target

kr392.28
▲(23.43%Upside)
Based on 2 Wall Street analysts offering 12 month price targets for Xvivo Perfusion AB in the last 3 months. The average price target is kr392.28 with a high forecast of kr459.75 and a low forecast of kr324.80. The average price target represents a 23.43% change from the last price of kr317.80.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"323":"kr323","460":"kr460","357.25":"kr357.3","391.5":"kr391.5","425.75":"kr425.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":459.7535420345,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr459.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":392.2756021415,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr392.28</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":324.7976622485,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr324.80</span>\n  </div></div>","useHTML":true}}],"tickPositions":[323,357.25,391.5,425.75,460],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2022","6":"Mar<br/>2023","9":"Jun<br/>2023","12":"Mar<br/>2025","25":"Mar<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,444,445.2118109257308,446.4236218514615,447.6354327771923,448.8472437029231,450.0590546286538,451.2708655543846,452.4826764801154,453.6944874058462,454.9062983315769,456.1181092573077,457.3299201830385,458.5417311087692,{"y":459.7535420345,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,444,440.02120016473077,436.04240032946154,432.0636004941923,428.0848006589231,424.10600082365386,420.12720098838463,416.14840115311534,412.1696013178461,408.1908014825769,404.21200164730766,400.23320181203843,396.2544019767692,{"y":392.2756021415,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,444,434.83058940373076,425.6611788074615,416.4917682111923,407.3223576149231,398.15294701865383,388.9835364223846,379.8141258261154,370.64471522984616,361.4753046335769,352.30589403730767,343.1364834410384,333.9670728447692,{"y":324.7976622485,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":328,"date":1661990400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":328,"date":1664582400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":328,"date":1667260800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":328,"date":1669852800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":328,"date":1672531200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":328,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":328,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":328,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":328,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":328,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":328,"date":1685577600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":418,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":444,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Targetkr459.75Average Price Targetkr392.28Lowest Price Targetkr324.80
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on SE:XVIVO
TipRanks AITipRanks
Not Ranked
TipRanks
kr341
Hold
7.30%
Upside
Reiterated
06/10/25
Xvivo Perfusion AB's overall stock score is driven primarily by its strong financial performance, evidenced by robust revenue growth and a solid balance sheet. However, mixed technical indicators and a high P/E ratio suggest caution. The absence of earnings call and corporate events data did not impact the evaluation.
Danske Bank Analyst forecast on SE:XVIVO
Erik CasselDanske Bank
Danske Bank
kr560kr325
Sell
2.27%
Upside
Downgraded
03/25/25
Xvivo Perfusion downgraded to Sell from Buy at Danske BankXvivo Perfusion downgraded to Sell from Buy at Danske Bank
Pareto Analyst forecast on SE:XVIVO
Filip WibergPareto
Not Ranked
Pareto
kr460
Buy
44.75%
Upside
Upgraded
03/25/25
Xvivo Perfusion upgraded to Buy from Hold at ParetoXvivo Perfusion upgraded to Buy from Hold at Pareto
Bryan Garnier & Co Ltd Analyst forecast on SE:XVIVO
Unknown AnalystBryan Garnier & Co Ltd
Not Ranked
Bryan Garnier & Co Ltd
kr480
Hold
51.04%
Upside
Downgraded
07/15/24
Xvivo Perfusion downgraded to Neutral from Buy at Bryan GarnierXvivo Perfusion downgraded to Neutral from Buy at Bryan Garnier
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on SE:XVIVO
TipRanks AITipRanks
Not Ranked
TipRanks
kr341
Hold
7.30%
Upside
Reiterated
06/10/25
Xvivo Perfusion AB's overall stock score is driven primarily by its strong financial performance, evidenced by robust revenue growth and a solid balance sheet. However, mixed technical indicators and a high P/E ratio suggest caution. The absence of earnings call and corporate events data did not impact the evaluation.
Danske Bank Analyst forecast on SE:XVIVO
Erik CasselDanske Bank
Danske Bank
kr560kr325
Sell
2.27%
Upside
Downgraded
03/25/25
Xvivo Perfusion downgraded to Sell from Buy at Danske BankXvivo Perfusion downgraded to Sell from Buy at Danske Bank
Pareto Analyst forecast on SE:XVIVO
Filip WibergPareto
Not Ranked
Pareto
kr460
Buy
44.75%
Upside
Upgraded
03/25/25
Xvivo Perfusion upgraded to Buy from Hold at ParetoXvivo Perfusion upgraded to Buy from Hold at Pareto
Bryan Garnier & Co Ltd Analyst forecast on SE:XVIVO
Unknown AnalystBryan Garnier & Co Ltd
Not Ranked
Bryan Garnier & Co Ltd
kr480
Hold
51.04%
Upside
Downgraded
07/15/24
Xvivo Perfusion downgraded to Neutral from Buy at Bryan GarnierXvivo Perfusion downgraded to Neutral from Buy at Bryan Garnier
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Xvivo Perfusion AB

1 Month
xxx
Success Rate
1/1 ratings generated profit
100%
Average Return
+6.40%
downgraded a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +6.40% per trade.
3 Months
xxx
Success Rate
1/1 ratings generated profit
100%
Average Return
+1.40%
downgraded a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +1.40% per trade.
1 Year
Erik CasselDanske Bank
Success Rate
1/1 ratings generated profit
100%
Average Return
+1.20%
downgraded a sell rating 3 months ago
Copying Erik Cassel's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +1.20% per trade.
2 Years
xxx
Success Rate
1/1 ratings generated profit
100%
Average Return
+1.40%
downgraded a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +1.40% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

XVIVO Analyst Recommendation Trends

Rating
Jun 23
Jul 24
Mar 25
Strong Buy
1
1
2
Buy
0
0
0
Hold
0
1
1
Sell
0
0
1
Strong Sell
0
0
0
total
1
2
4
In the current month, XVIVO has received 2 Buy Ratings, 1 Hold Ratings, and 1 Sell Ratings. XVIVO average Analyst price target in the past 3 months is 392.28.
Each month's total comprises the sum of three months' worth of ratings.

XVIVO Financial Forecast

XVIVO Earnings Forecast

Next quarter’s earnings estimate for XVIVO is kr0.94 with a range of kr0.93 to kr0.94. The previous quarter’s EPS was -kr0.39. XVIVO beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 38.71% of the time in the same period. In the last calendar year XVIVO has Outperformed its overall industry.
Next quarter’s earnings estimate for XVIVO is kr0.94 with a range of kr0.93 to kr0.94. The previous quarter’s EPS was -kr0.39. XVIVO beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 38.71% of the time in the same period. In the last calendar year XVIVO has Outperformed its overall industry.

XVIVO Sales Forecast

Next quarter’s sales forecast for XVIVO is kr236.67M with a range of kr231.00M to kr240.00M. The previous quarter’s sales results were kr218.59M. XVIVO beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.35% of the time in the same period. In the last calendar year XVIVO has Outperformed its overall industry.
Next quarter’s sales forecast for XVIVO is kr236.67M with a range of kr231.00M to kr240.00M. The previous quarter’s sales results were kr218.59M. XVIVO beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.35% of the time in the same period. In the last calendar year XVIVO has Outperformed its overall industry.

XVIVO Stock Forecast FAQ

What is SE:XVIVO’s average 12-month price target, according to analysts?
Based on analyst ratings, Xvivo Perfusion AB’s 12-month average price target is 392.28.
    What is SE:XVIVO’s upside potential, based on the analysts’ average price target?
    Xvivo Perfusion AB has 23.43% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Xvivo Perfusion AB a Buy, Sell or Hold?
          Xvivo Perfusion AB has a consensus rating of Hold, which is based on 1 buy ratings, 0 hold ratings and 1 sell ratings.
            What is Xvivo Perfusion AB’s share price target?
            The average share price target for Xvivo Perfusion AB is 392.28. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is kr459.75 ,and the lowest forecast is kr324.80. The average share price target represents 23.43% Increase from the current price of kr317.8.
              What do analysts say about Xvivo Perfusion AB?
              Xvivo Perfusion AB’s analyst rating consensus is a Hold. This is based on the ratings of 2 Wall Streets Analysts.
                How can I buy shares of Xvivo Perfusion AB?
                To buy shares of SE:XVIVO, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis